1-O-Acetylgeopyxin A, a derivative of a fungal metabolite, blocks tetrodotoxin-sensitive voltage-gated sodium, calcium channels and neuronal excitability which correlates with inhibition of neuropathic pain.
Action Potentials
/ drug effects
Animals
Calcium Channel Blockers
/ pharmacology
Calcium Channels
/ drug effects
Female
Ganglia, Spinal
/ cytology
HIV Infections
/ drug therapy
Hyperalgesia
/ drug therapy
Limonins
/ administration & dosage
Neuralgia
/ drug therapy
Nociceptors
/ drug effects
Pharmaceutical Preparations
/ administration & dosage
Rats
Rats, Sprague-Dawley
Sodium Channel Blockers
/ pharmacology
Sodium Channels
/ drug effects
Tetrodotoxin
/ pharmacology
1-O-acetylgeopyxin a
Excitability
HIV-induced sensory neuropathy
Non-opioid pain-relieving therapeutics
Tetrodotoxin-sensitive voltage-gated sodium channels
Voltage-gated calcium channels
Voltage-gated sodium channels
Journal
Molecular brain
ISSN: 1756-6606
Titre abrégé: Mol Brain
Pays: England
ID NLM: 101468876
Informations de publication
Date de publication:
11 05 2020
11 05 2020
Historique:
received:
03
03
2020
accepted:
04
05
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
4
6
2021
Statut:
epublish
Résumé
Chronic pain can be the result of an underlying disease or condition, medical treatment, inflammation, or injury. The number of persons experiencing this type of pain is substantial, affecting upwards of 50 million adults in the United States. Pharmacotherapy of most of the severe chronic pain patients includes drugs such as gabapentinoids, re-uptake blockers and opioids. Unfortunately, gabapentinoids are not effective in up to two-thirds of this population and although opioids can be initially effective, their long-term use is associated with multiple side effects. Therefore, there is a great need to develop novel non-opioid alternative therapies to relieve chronic pain. For this purpose, we screened a small library of natural products and their derivatives in the search for pharmacological inhibitors of voltage-gated calcium and sodium channels, which are outstanding molecular targets due to their important roles in nociceptive pathways. We discovered that the acetylated derivative of the ent-kaurane diterpenoid, geopyxin A, 1-O-acetylgeopyxin A, blocks voltage-gated calcium and tetrodotoxin-sensitive voltage-gated sodium channels but not tetrodotoxin-resistant sodium channels in dorsal root ganglion (DRG) neurons. Consistent with inhibition of voltage-gated sodium and calcium channels, 1-O-acetylgeopyxin A reduced reduce action potential firing frequency and increased firing threshold (rheobase) in DRG neurons. Finally, we identified the potential of 1-O-acetylgeopyxin A to reverse mechanical allodynia in a preclinical rat model of HIV-induced sensory neuropathy. Dual targeting of both sodium and calcium channels may permit block of nociceptor excitability and of release of pro-nociceptive transmitters. Future studies will harness the core structure of geopyxins for the generation of antinociceptive drugs.
Identifiants
pubmed: 32393368
doi: 10.1186/s13041-020-00616-2
pii: 10.1186/s13041-020-00616-2
pmc: PMC7216607
doi:
Substances chimiques
1-O-acetylkhayanolide A
0
Calcium Channel Blockers
0
Calcium Channels
0
Limonins
0
Pharmaceutical Preparations
0
Sodium Channel Blockers
0
Sodium Channels
0
Tetrodotoxin
4368-28-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Subventions
Organisme : NINDS NIH HHS
ID : R01 NS098772
Pays : United States
Références
Epilepsy Res. 1993 Oct;16(2):89-98
pubmed: 7505742
Neurosci Lett. 2015 Jun 2;596:51-9
pubmed: 25556685
Trends Neurosci. 2007 Nov;30(11):555-63
pubmed: 17950472
Planta Med. 2010 Feb;76(2):140-5
pubmed: 19653147
Cell Rep. 2018 Feb 27;22(9):2307-2321
pubmed: 29490268
Elife. 2019 Nov 25;8:
pubmed: 31765298
J Neurosci. 2009 Apr 1;29(13):4076-88
pubmed: 19339603
Mol Pharmacol. 2011 Nov;80(5):900-10
pubmed: 21821734
Trends Neurosci. 2002 May;25(5):253-9
pubmed: 11972962
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8443-E8452
pubmed: 27940916
J Physiol. 2003 Sep 15;551(Pt 3):741-50
pubmed: 12843211
Nat Med. 2011 Jun 05;17(7):822-9
pubmed: 21642979
Neuron. 1992 Dec;9(6):1099-115
pubmed: 1334419
Ann Neurol. 2014 Jun;75(6):837-50
pubmed: 24633867
J Nat Prod. 2004 Jan;67(1):2-4
pubmed: 14738375
J Clin Invest. 2010 Nov;120(11):3742-4
pubmed: 21041955
Mol Pain. 2012 Jul 24;8:54
pubmed: 22828369
Clin Sci (Lond). 2016 Dec 1;130(24):2257-2265
pubmed: 27815510
J Neurophysiol. 2008 Jun;99(6):3151-6
pubmed: 18417624
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9382-7
pubmed: 15964986
ACS Chem Neurosci. 2019 Jun 19;10(6):2939-2955
pubmed: 30946560
Physiol Behav. 1976 Dec;17(6):1031-6
pubmed: 14677603
Pain. 2010 Jul;150(1):183-91
pubmed: 20546998
Pain. 2017 Nov;158(11):2203-2221
pubmed: 28767512
Lancet Neurol. 2014 Nov;13(11):1152-1160
pubmed: 25316021
Planta Med. 2005 Oct;71(10):904-9
pubmed: 16254820
Planta Med. 2001 Jul;67(5):406-10
pubmed: 11488452
J Nat Prod. 2009 Mar 27;72(3):500-2
pubmed: 19215141
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
Pain. 2017 Dec;158(12):2301-2319
pubmed: 28809766
Br J Pharmacol. 2018 Jun;175(12):2244-2260
pubmed: 28161890
J Neurosci. 2020 Jan 8;40(2):283-296
pubmed: 31744861
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12706-11
pubmed: 15314237
Neuron. 2003 Jul 31;39(3):483-96
pubmed: 12895422
J Neurosci. 1992 Jun;12(6):2104-11
pubmed: 1318956
J Biol Chem. 2013 Aug 23;288(34):24316-31
pubmed: 23836888
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):1-8
pubmed: 11687271
J Neurosci. 2010 Jan 20;30(3):1073-85
pubmed: 20089916
Exp Brain Res. 2002 Dec;147(4):456-63
pubmed: 12444477
J Nat Prod. 2008 Nov;71(11):1930-3
pubmed: 18986201
J Nat Prod. 2000 May;63(5):599-601
pubmed: 10843567
Cell. 2009 Oct 16;139(2):380-92
pubmed: 19818485
Lancet. 1999 Jun 12;353(9169):2051-8
pubmed: 10376632
Pain. 2015 Jul;156(7):1247-64
pubmed: 25782368
J Neurosci. 2001 Mar 15;21(6):1868-75
pubmed: 11245671
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
J Cell Sci. 2009 Dec 1;122(Pt 23):4351-62
pubmed: 19903690
EMBO J. 2005 Jan 26;24(2):315-24
pubmed: 15616581
Planta Med. 2010 May;76(7):721-5
pubmed: 20013639
Cell. 2012 May 25;149(5):1112-24
pubmed: 22632974
J Biol Chem. 2012 Jan 20;287(4):2810-8
pubmed: 22130660
Pain. 2012 Oct;153(10):2017-30
pubmed: 22703890
Ann Pharmacother. 2006 Jul-Aug;40(7-8):1293-300
pubmed: 16849624
J Pharmacol Exp Ther. 1994 Jun;269(3):1117-23
pubmed: 8014856
J Neurophysiol. 2001 Aug;86(2):629-40
pubmed: 11495938
J Neurosci. 2001 Apr 15;21(8):2808-19
pubmed: 11306633
J Nat Prod. 2012 Mar 23;75(3):361-9
pubmed: 22264149
Trends Pharmacol Sci. 2009 Jan;30(1):32-40
pubmed: 19042038
Molecules. 2020 Jan 29;25(3):
pubmed: 32013210
J Nat Prod. 2007 Mar;70(3):347-52
pubmed: 17378530
ACS Chem Neurosci. 2019 Mar 20;10(3):1716-1728
pubmed: 30525440
Pain. 2019 Jan;160(1):117-135
pubmed: 30169422
Neuron. 2008 Sep 25;59(6):882-901
pubmed: 18817729